Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings.
Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim SMID Cap Biotech Conference at 1:30 PM ET on February 6th hosted at the Lotte New York Palace in New York, NY.
Additionally, on March 3rd at 10:30 AM ET, Dr. Wagner will be presenting at the TD Cowen 45th Annual Healthcare Conference hosted at the Boston Marriott Copley Place in Boston, MA.
About Forte
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.
Source: Forte Biosciences, Inc.
Contacts
LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com